Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees

Journal of Viral Hepatitis

Volumn 9, Issue 6, 2002, Pages 400-410

  Shata, M T ^a   Anthony, D D ^b   Carlson, N L ^b   Andrus, L ^a   Brotman, B ^a   Tricoche, N ^a   McCormack, P ^a   Prince, A ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Core peptides; Hepatitis C; Immune response; NS3 peptides; TNF

Indexed keywords

CYTOKINE; EPITOPE; GAMMA INTERFERON; HEPATITIS C ANTIBODY; PEPTIDE; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CHIMPANZEE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; FEMALE; HEPATITIS C; IMMUNE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; TIME;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; PAN TROGLODYTES; PEPTIDES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0036440527     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00373.x     Document Type: Article

References (49)

1. Alter MJ et al. Prevalence hepatitis C virus infection United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
2. Seeff LB et al. Long-term mortality and morbidity of transfusion-associated non-A, non- B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-463.
3. Abe K et al. Three different patterns of hepatitis C virus infection in chimpanzees. Hepatology 1992; 15: 690-695.
4. Prince AM, Brotman B. The biology of hepatitis C virus infection. Lessons learned from chimpanzees. Curr Stud Hematol Blood Transfus 1994; 61: 195-207.
5. Wang YF et al. Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees. J Infect Dis 1996; 173: 808-821.
6. Thursz MR. Host genetic factors influencing the outcome of hepatitis. J Viral Hepat 1997; 4: 215-220.
7. Inchauspe G. Protection and defence mechanisms in HCV infection. Nephrol Dial Transplant 1996; 11 (Suppl. 4): 6-8.
8. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000; 20: 127-141.
9. Cooper S et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-449.
10. Lewalle P et al. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli. J Immunol Meth 2000; 240: 69-78.
11. Koch E, Larak M, Ellendorff F. Comparative studies on in vitro reactivity of fresh and cryopreserved pig lymphocytes. Cryobiology 1991; 28: 405-412.
12. Lai J et al. A simplified method for PCR detection of hepatitis C virus RNA from human serum. PCR Meth Appl 1994; 3: 308-309.
13. Takeuchi T et al. Real-time detection system for quantification of hepatitis C virus genome [see comments]. Gastroenterology 1999; 116: 636-642.
14. Choo QL et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 2451-2455.
15. Takamizawa A et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991; 65: 1105-1113.
16. Tartaglia J et al. NYVAC. A highly attenuated strain of vaccinia virus. Virology 1992; 188: 217-232.
17. Panicali D et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol 1981; 37: 1000-1010.
18. Perkus ME, Limbach K, Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol 1989; 63: 3829-3836.
19. Yuen L, Moss B. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci USA 1987; 84: 6417-6421.
20. Tsai SL et al. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449-458.
21. Rosen HR et al. Association of multispecific CD4 (+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117: 926-932.
22. Wong DK et al. Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV. J Virol 2001; 75: 1229-1235.
23. Cohard M et al. Hepatitis C virus-specific CTL responses in PBMC from chimpanzees with chronic hepatitis C. determination of CTL and CTL precursor frequencies using a recombinant canarypox virus (ALVAC). J Immunol Meth 1998; 214: 121-129.
24. Anthony D, Valdez H, Post AB, Carlson NL, Heeger PS, Lehmann PV. Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy. Clin Immunol 2002; 103: 264-276.
25. Wedemeyer H et al. Cross-reactivity between hepatitis C virus and influenza: A virus determinant-specific cytotoxic T cell. J Virol 2001; 75: 11392-11400.
26. Ionita E et al. [False-positive ELISA reactions for the hepatitis C virus and the human immunodeficiency virus after anti-influenzal vaccination]. Bacteriol Virusol Parazitol Epidemiol 1995; 40: 249-252.
27. Lalvani A et al. Rapid effector function in CD8+ memory T cells. J Exp Med 1997; 186: 859-865.
28. Lalvani A et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1998; 95: 270-275.
29. + T cells using an ELISPOT assay. J Immunol Meth 1995; 181: 45-54.
30. Wentworth PA et al. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 1996; 8: 651-659.
31. Ferrari C et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286-295.
32. Diepolder HM et al. The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med 1996; 74: 583-588.
33. He XS et al. Quantitative analysis of hepatitis C virus-specific CD8 (+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999; 96: 5692-5697.
34. Nelson DR et al. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28: 225-230.
35. Jin Y et al. The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage. J Clin Immunol 1997; 17: 140-153.
36. Cerny A, Chisari FV. Immunological aspects of HCV infection. Intervirology 1994; 37: 119-125.
37. Takaki A et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582.
38. Vandelli C et al. Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C. J Med Virol 1999; 58: 26-34.
39. Pancholi P et al. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J Infect Dis 2000; 182: 18-27.
40. Rehermann B et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97: 1655-1665.
41. Koziel MJ. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat 1997; 4 (Suppl. 2): 31-41.
42. Erickson AL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993; 151: 4189-4199.
43. Berzofsky JA et al. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol Rev 1999; 170: 151-172.
44. Zhang DF et al. Serum tumor necrosis factor (TNF) in the pathogenesis of clinical hepatic failure of HCV and/or HBV infection. Chin Med J (Engl) 1993; 106: 335-338.
45. Ando K et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158: 5283-5291.
46. Kakumu S et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997; 109: 458-463.
47. Jonuleit H et al. Induction of interleukin 10-producing, nonproliferating CD4 (+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells [In Process Citation]. J Exp Med 2000; 192: 1213-1222.
48. Koziel MJ et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995; 96: 2311-2321.
49. Erickson AL et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 883-895.